Additional file 1 of Identification of indications for albumin administration in septic patients with liver cirrhosis
Creators: name: Hu, Wenhan
name: Chen, Hui
name: Ma, Chencheng
name: Sun, Qin
name: Yang, Meicheng
name: Wang, Haofei
name: Peng, Qingyun
name: Wang, Jinlong
name: Zhang, Chen
name: Huang, Wei
name: Xie, Jianfeng
name: Huang, Yingzi
Publisher: name: figshare
Year: 2023
Subjects: subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Physiology
subject: FOS: Biological sciences
subject: Biotechnology
subject: Environmental Sciences not elsewhere classified
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Science Policy
subject: Computational Biology

description: Additional file 1: Additional method. Table S1: Selection strategy for variables with multiple measurements. Table S2: Infection category codes from ICD-9-CM to ICD-10-CM. Table S3: Missing rate for demographics and clinical variables extracted from the database during the observation period. Table S4: Missing rate for demographics and clinical variables extracted from the database on the first day. Table S5: Thresholds for clinical variables as albumin therapy indication. Table S6: Multivariable Cox model with time-fixed and time-dependent covariates for 28-day mortality adding to the model the effect of albumin administration, weighted with marginal structural models. Table S7: Association between albumin administration and 28-day mortality estimated by extended Cox regression model with time-varying covariates. Table S8: Univariate and multivariate analyses weighted with MSCM of the association between albumin infusion and 28-day mortality in patients after the exclusion of spontaneous bacterial peritonitis. Table S9: Multivariable Cox model with time-fixed and time-dependent covariates for 28-day mortality adding to the model the effect of albumin administration, weighted with marginal structural models. The analysis was repeated until reaching the highest level of serum albumin concentration, for which the albumin infusion still showed a positive effect on the outcome. Table S10: Multivariable Cox model with time-fixed and time-dependent covariates for 28-day mortality adding to the model the effect of albumin administration, weighted with marginal structural models. The analysis was repeated until reaching the lowest level of serum lactate concentration, for which the albumin infusion still showed a positive effect on the outcome. Table S11: Correlation between the types of albumin solutions administered and 28-day mortality as estimated by the MSCM. Figure S1: Directed acyclic graph (DAG) illustrating the potential actions of confounding covariates on the relation between the administration of albumin according to different albumin concentrations and clinical outcomes. Figure S2: Correlation matrix for time-fixed covariates. Figure S3: Correlation matrix for time-dependent covariates. Figure S4: Variable selection for Cox time-dependent and time-independent model factors associated with 28-day mortality. Figure S5: Schematic illustrations of the sub-cohort establishment. Figure S6: Expanded Kaplan–Meier survival analysis, weighted by marginal structural models. Figure S7: Distribution of inverse probability weight in albumin and non-albumin groups. Figure S8: Adjusted risk of death at 28 days measured by Marginal Structural Cox proportional hazards Model according to baseline subgroups.